title: Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function.
abstract: The pharmacokinetics of 14C-labeled glyburide were studied in 13 men with varying degrees of renal impairment. Patients received a single, 5 mg oral dose of glyburide as a solution (10 microCi/ml/mg) after a high-carbohydrate breakfast. Serial plasma and breath samples were collected for 48 hours and urine and feces were collected for 5 to 7 days. Patients with normal to moderately impaired renal function (creatinine clearance [CLCR] of 29 to 131 ml/min/1.7 m2) had glyburide plasma t1/2 values of 2.0 to 5.0 hours, with no relationship between CLCR and glyburide clearance. One subject with severe renal impairment (CLCR = 5 ml/min/1.7 m2) had decreased glyburide clearance that resulted in a t1/2 of 11 hours. The elimination of metabolites was more dependent on renal status but was only significantly affected in the patient with severe renal impairment.
authors.forename: J G
authors.initials: JG
authors.lastname: Pearson
authors.forename: E J
authors.initials: EJ
authors.lastname: Antal
authors.forename: C L
authors.initials: CL
authors.lastname: Raehl
authors.forename: H K
authors.initials: HK
authors.lastname: Gorsch
authors.forename: W A
authors.initials: WA
authors.lastname: Craig
authors.forename: K S
authors.initials: KS
authors.lastname: Albert
authors.forename: P G
authors.initials: PG
authors.lastname: Welling
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001944:Breath Tests; D002250:Carbon Radioisotopes; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000032:analysis; D005243:Feces / Q000032:analysis; D005905:Glyburide / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged
chemical_list: D002250:Carbon Radioisotopes; D003404:Creatinine; D005905:Glyburide